CN102458113A - 与缺血再灌注相关的水肿的治疗方法 - Google Patents

与缺血再灌注相关的水肿的治疗方法 Download PDF

Info

Publication number
CN102458113A
CN102458113A CN2010800259139A CN201080025913A CN102458113A CN 102458113 A CN102458113 A CN 102458113A CN 2010800259139 A CN2010800259139 A CN 2010800259139A CN 201080025913 A CN201080025913 A CN 201080025913A CN 102458113 A CN102458113 A CN 102458113A
Authority
CN
China
Prior art keywords
tissue
compound
reperfusion
organ
lung
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2010800259139A
Other languages
English (en)
Chinese (zh)
Inventor
T·M·埃甘
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of North Carolina at Chapel Hill
Original Assignee
University of North Carolina at Chapel Hill
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of North Carolina at Chapel Hill filed Critical University of North Carolina at Chapel Hill
Publication of CN102458113A publication Critical patent/CN102458113A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00—Preservation of bodies of humans or animals, or parts thereof
    • A01N1/10—Preservation of living parts
    • A01N1/12—Chemical aspects of preservation
    • A01N1/122—Preservation or perfusion media
    • A01N1/126—Physiologically active agents, e.g. antioxidants or nutrients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Environmental Sciences (AREA)
  • Dentistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
CN2010800259139A 2009-04-09 2010-04-09 与缺血再灌注相关的水肿的治疗方法 Pending CN102458113A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16808909P 2009-04-09 2009-04-09
US61/168,089 2009-04-09
PCT/US2010/030556 WO2010118334A1 (en) 2009-04-09 2010-04-09 Methods of treating edema related to ischemia-reperfusion

Publications (1)

Publication Number Publication Date
CN102458113A true CN102458113A (zh) 2012-05-16

Family

ID=42936599

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2010800259139A Pending CN102458113A (zh) 2009-04-09 2010-04-09 与缺血再灌注相关的水肿的治疗方法

Country Status (14)

Country Link
US (1) US20120064044A1 (cg-RX-API-DMAC7.html)
EP (1) EP2416651A4 (cg-RX-API-DMAC7.html)
JP (1) JP2012523432A (cg-RX-API-DMAC7.html)
KR (1) KR20120005025A (cg-RX-API-DMAC7.html)
CN (1) CN102458113A (cg-RX-API-DMAC7.html)
AU (1) AU2010233151A1 (cg-RX-API-DMAC7.html)
BR (1) BRPI1010516A2 (cg-RX-API-DMAC7.html)
CA (1) CA2757998A1 (cg-RX-API-DMAC7.html)
EA (1) EA201101349A1 (cg-RX-API-DMAC7.html)
IL (1) IL215604A0 (cg-RX-API-DMAC7.html)
MX (1) MX2011010616A (cg-RX-API-DMAC7.html)
SG (1) SG175133A1 (cg-RX-API-DMAC7.html)
WO (1) WO2010118334A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201107815B (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009126822A2 (en) 2008-04-09 2009-10-15 The University Of North Carolina At Chapel Hill Methods of regulating actin cytoskeletal rearrangement and intercellular gap formation
EP2681314B1 (en) 2011-03-03 2017-11-01 Quark Pharmaceuticals, Inc. Compositions and methods for treating lung disease and injury
US10531655B2 (en) 2011-12-02 2020-01-14 The Regents Of The University Of California Reperfusion protection solution and uses thereof
WO2018165656A1 (en) 2017-03-10 2018-09-13 The University Of North Carolina At Chapel Hill Short-acting heparin-based anticoagulant compounds and methods
US11993627B2 (en) 2017-07-03 2024-05-28 The University Of North Carolina At Chapel Hill Enzymatic synthesis of homogeneous chondroitin sulfate oligosaccharides
US11865137B2 (en) 2017-11-03 2024-01-09 The University Of North Carolina At Chapel Hill Sulfated oligosaccharides having anti-inflammatory activity
BR112020016314A2 (pt) 2018-02-12 2020-12-15 Inimmune Corporation Compostos ou um sais farmaceuticamente aceitáveis, composição farmacêutica, kit, e, métodos para elicitar, intensificar ou modificar uma resposta imunológica, para tratar, prevenir ou reduzir a suscetibilidade a câncer, para tratar, prevenir ou reduzir a suscetibilidade a uma doença infecciosa, para tratar, prevenir ou reduzir a suscetibilidade a uma alergia, para tratar, prevenir ou reduzir a suscetibilidade a uma afecção autoimune, para tratar, prevenir ou reduzir a suscetibilidade em um sujeito à infecção bacteriana, viral, priônica, autoimunidade, câncer ou alergia, para tratar, prevenir ou reduzir a suscetibilidade à autoimunidade, alergia, reperfusão de isquemia ou sepse, para tratar, prevenir ou reduzir a gravidade de ataques epiléticos e para tratar, prevenir ou reduzir a suscetibilidade a doenças oculares como degeneração macular, hipertensão ocular e infecção ocular
WO2019246264A1 (en) 2018-06-20 2019-12-26 The University Of North Carolina At Chapel Hill Cell protective methods and compositions
WO2021097345A1 (en) * 2019-11-13 2021-05-20 The University Of North Carolina At Chapel Hill Heparan sulfate (hs) oligosaccharides effect in liver ischemia reperfusion injury

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1265112A (zh) * 1997-05-08 2000-08-30 科里克萨有限公司 氨基烷基葡萄糖胺磷酸酯化合物及其作为佐剂和免疫效应物的用途
US20050227943A1 (en) * 2003-01-06 2005-10-13 Corixa Corporation Certain aminoalkyl glucosaminide phosphate compounds and their use
US20060058365A1 (en) * 2004-08-06 2006-03-16 Kohn Leonard D Compositions and methods for treatment of colitis
US20060211752A1 (en) * 2004-03-16 2006-09-21 Kohn Leonard D Use of phenylmethimazoles, methimazole derivatives, and tautomeric cyclic thiones for the treatment of autoimmune/inflammatory diseases associated with toll-like receptor overexpression
WO2009019260A2 (en) * 2007-08-03 2009-02-12 Opsona Therapeutics Limited Composition and method for treatment of reperfusion injury and tissue damage

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05139992A (ja) * 1991-11-13 1993-06-08 Ajinomoto Co Inc ヒトadfを含有する臓器保護剤
WO2004085396A1 (ja) * 2003-03-26 2004-10-07 Mitsubishi Pharma Corporation 虚血再灌流障害の予防または治療剤、臓器保存剤およびスクリーニング方法
WO2009126822A2 (en) * 2008-04-09 2009-10-15 The University Of North Carolina At Chapel Hill Methods of regulating actin cytoskeletal rearrangement and intercellular gap formation

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1265112A (zh) * 1997-05-08 2000-08-30 科里克萨有限公司 氨基烷基葡萄糖胺磷酸酯化合物及其作为佐剂和免疫效应物的用途
US20050227943A1 (en) * 2003-01-06 2005-10-13 Corixa Corporation Certain aminoalkyl glucosaminide phosphate compounds and their use
US20060211752A1 (en) * 2004-03-16 2006-09-21 Kohn Leonard D Use of phenylmethimazoles, methimazole derivatives, and tautomeric cyclic thiones for the treatment of autoimmune/inflammatory diseases associated with toll-like receptor overexpression
US20060058365A1 (en) * 2004-08-06 2006-03-16 Kohn Leonard D Compositions and methods for treatment of colitis
WO2009019260A2 (en) * 2007-08-03 2009-02-12 Opsona Therapeutics Limited Composition and method for treatment of reperfusion injury and tissue damage

Also Published As

Publication number Publication date
KR20120005025A (ko) 2012-01-13
AU2010233151A1 (en) 2011-11-17
BRPI1010516A2 (pt) 2015-08-25
EA201101349A1 (ru) 2012-05-30
MX2011010616A (es) 2012-03-14
EP2416651A1 (en) 2012-02-15
CA2757998A1 (en) 2010-10-14
US20120064044A1 (en) 2012-03-15
WO2010118334A1 (en) 2010-10-14
JP2012523432A (ja) 2012-10-04
EP2416651A4 (en) 2014-03-26
SG175133A1 (en) 2011-12-29
ZA201107815B (en) 2013-04-24
IL215604A0 (en) 2011-12-29

Similar Documents

Publication Publication Date Title
US20120064044A1 (en) Methods of treating edema related to ischemia-reperfusion
Moskowitzova et al. Mitochondrial transplantation prolongs cold ischemia time in murine heart transplantation
Li et al. Bone marrow‐derived mesenchymal stem cells enhance autophagy via PI 3K/AKT signalling to reduce the severity of ischaemia/reperfusion‐induced lung injury
JP5607176B2 (ja) 新規ペプチドおよびその用途
Li et al. Fusaric acid (FA) protects heart failure induced by isoproterenol (ISP) in mice through fibrosis prevention via TGF-β1/SMADs and PI3K/AKT signaling pathways
JP7538724B2 (ja) 細胞保護の方法と組成物
Nishimura Role of the renin-angiotensin system in osmoregulation
JP5264478B2 (ja) 活性物質での細胞表面の装飾
WO2015074139A1 (en) Polymer based transplant preservation solution
JP2020536048A (ja) 発毛を調節するための組成物及び方法
CN102083443B (zh) 调节肌动蛋白细胞骨架重排和细胞间间隙形成的方法
ES2268071T3 (es) Vesiculas naturales que mimetizan la apoptosis y uso de las msimas en tratamiento medico.
ES2481645T3 (es) Tratamiento de fibrosis y enfermedades hepáticas
CN116284175A (zh) 一种小分子化合物及其在制备治疗慢性肾脏病药物中的应用
KR20220149245A (ko) 조골세포 미토콘드리아에 작용하여 골형성 촉진 유도용 또는 골질환 치료용 조성물
Schep et al. Permeability of the salmon (Oncorhynchus tshawytscha) posterior intestine in vivo to two hydrophilic markers
JP2022083279A (ja) 腎臓保護用の組成物
Wada et al. Effects of Perfluorochemical‐Based Artificial Blood Compounds in Discordant Xenotransplantation
CN103989701B (zh) 聚乙二醇4000或聚乙二醇6000在制备预防或治疗水母毒素心脏毒性药物中的应用
CN115518158A (zh) mTOR抑制剂体外诱导树突状细胞及其应用
Kato et al. Effect of epidermal growth factor on intestinal adaptation after allogeneic small bowel transplantation in rats
WO2007099711A1 (ja) 分化誘導剤
LYSOPHOSPHATIDIC POTENTIAL ROLE OF BACTERIAL CPG DNA IN THE PATHOGENESIS

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20120516

WD01 Invention patent application deemed withdrawn after publication